
Vascular Malformations- Pipeline Insight, 2024
Description
Vascular Malformations- Pipeline Insight, 2024
DelveInsight’s, “Vascular Malformations- Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Vascular Malformations pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Vascular Malformations: Overview
Vascular malformations are abnormal connections between blood or lymph vessels. They are typically present at birth (congenital) but may also develop during one’s lifetime. Vascular malformations are grouped together based upon their common embryological origin of having a single endothelial cell lining. Vascular malformations are thought to result from developmental errors during embryogenesis, such as abnormal signaling processes that control apoptosis, maturation, and growth of vascular cells. These errors lead to the persistence of vascular plexus cells with a certain degree of differentiation. There are four major categories of vascular malformations based on their flow characteristics: slow-flow (capillary malformation, venous malformation, lymphatic malformation) and fast-flow (arteriovenous malformation). Symptoms of vascular malformations depend on their size and location. The most common symptoms include: Pain Swelling, skin discoloration color in the area of the malformation. Some people with high-flow vascular malformations can become short of breath and tire easily during activities. The skin over a vascular malformation may be warm and discolored. In addition, skin could: Become tender, bleed, bruise easily and break down. For venous malformations, although surgery is sometimes useful, it is usually difficult for surgeons to completely remove vascular malformations, which will return if not removed completely. A nonsurgical method of closing down the blood or lymph flow into the malformation is done by interventional radiologists, who treat patients with image guided procedures. Vascular malformations are treated by embolization. The AVMs and hemangiomas can be closed by advancing a tiny plastic tubing, no larger than a pencil point, into the feeding artery to the malformation. This can be done without incisions or stitches, and with only mild sedation. Medical glue or alcohol or small beads are then floated into the malformation until it is full and no longer has blood flowing through it. For Pulmonary AVMs platinum coils are used to block flow through the feeding artery to the malformation. The VMs and LMs are closed by injecting alcohol into the sacs filled with venous blood or lymph until these sacs collapse and no longer fill. The arteriovenous malformations can be treated with a one-night hospital stay. There is usually minimal discomfort for one to three days. The venous and lymphatic malformations also require one night in the hospital. These malformations swell after treatment with alcohol, and the swelling and pain may last for three to five days. During this time, patients medication are given for any pain or swelling they may have. The full shrinkage of these malformations may take four to six weeks.
""Vascular Malformations- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Malformations pipeline landscape is provided which includes the disease overview and Vascular Malformations treatment guidelines. The assessment part of the report embraces, in depth Vascular Malformations commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Malformations collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Malformations R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Malformations.
This segment of the Vascular Malformations report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular Malformations Emerging Drugs
- VT 30: Venthera
- NPC-12: Nobelpharma
Further product details are provided in the report……..
Vascular Malformations: Therapeutic Assessment
This segment of the report provides insights about the different Vascular Malformations drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Vascular Malformations
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Vascular Malformations: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vascular Malformations therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Malformations drugs.
Vascular Malformations Report Insights
- Vascular Malformations Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Vascular Malformations drugs?
- How many Vascular Malformations drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Malformations?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Malformations therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vascular Malformations and their status?
- What are the key designations that have been granted to the emerging drugs?
- Nobelpharma
- Venthera
- ONY Biotech
- Vaderis Therapeutics
- BridgeBio Pharma
- Genentech, Inc.
- VT 30
- NPC-12
- VAD 044
- Acellular Tissue Engineered Vessels (ATEV)
- Cobimetinib
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Vascular Malformations: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Vascular Malformations– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- NPC-12: Nobelpharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/II)
- Comparative Analysis
- VT 30: Venthera
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Vascular Malformations Key Companies
- Vascular Malformations Key Products
- Vascular Malformations- Unmet Needs
- Vascular Malformations- Market Drivers and Barriers
- Vascular Malformations- Future Perspectives and Conclusion
- Vascular Malformations Analyst Views
- Vascular Malformations Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.